Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Journal of Molecular and Cellular Cardiology|January 11, 2012
Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knock out miceVedat Tiyerili, Cornelius F H Mueller, Ulrich M Becher, et al.
European Heart Journal|September 3, 2015
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillationA John Camm, Pierre Amarenco, Sylvia Haas, et al.
Cardiovascular Research|January 23, 2004
Sex-specific differences in ventricular expression and function of parathyroid hormone-related peptideChristian Grohé, Martin van Eickels, Sibylle Wenzel, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|July 2, 2019
Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTEWalter Ageno, Lorenzo G Mantovani, Sylvia Haas, et al.
The American Journal of Cardiology|February 8, 2011
Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial)Richard L Page, Stuart J Connolly, Harry J G M Crijns, et al.
European Heart Journal|May 4, 2010
Dronedarone in patients with congestive heart failure: insights from ATHENAStefan H Hohnloser, Harry J G M Crijns, Martin van Eickels, et al.
The New England Journal of Medicine|February 14, 2009
Effect of dronedarone on cardiovascular events in atrial fibrillationStefan H Hohnloser, Harry J G M Crijns, Martin van Eickels, et al.
Circulation|September 16, 2009
Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutterStuart J Connolly, Harry J G M Crijns, Christian Torp-Pedersen, et al.
American Heart Journal|March 31, 2015
Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF)Gregory Y H Lip, Christoph Hammerstingl, Francisco Marin, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 22, 2015
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trialStefan H Hohnloser, Riccardo Cappato, Michael D Ezekowitz, et al.
Pageof 6